Illumina Funds Report Alamar Biosciences Stock Changes
Ticker: ALMR · Form: 4 · Filed: Apr 21, 2026 · CIK: 0002104204
Sentiment: neutral
Topics: insider-filing, ownership-change, sec-form-4
Related Tickers: ALMR
TL;DR
Illumina funds adjusted Alamar Biosciences holdings on 4/16/26.
AI Summary
On April 16, 2026, Illumina Innovation Fund II, L.P. reported a change in beneficial ownership of Alamar Biosciences, Inc. securities. Nicholas Naclerio, associated with Illumina Innovation Fund II, L.P. and Illumina Innovation Fund II GP, L.L.C., also had changes reported. The filing details transactions related to Alamar Biosciences, Inc. stock.
Why It Matters
This filing indicates potential shifts in significant holdings for Alamar Biosciences, Inc. by entities linked to Illumina, which could signal strategic adjustments or investment decisions.
Risk Assessment
Risk Level: medium — Form 4 filings can indicate insider activity, which may precede significant stock price movements, but the specific impact depends on the nature and volume of the transactions.
Key Numbers
- 2026-04-16 — Period of Report (Date of reported stock transactions)
- 2026-04-20 — Filing Date (Date the report was officially submitted)
Key Players & Entities
- Alamar Biosciences, Inc. (company) — Issuer of securities
- Illumina Innovation Fund II, L.P. (company) — Reporting entity for stock transactions
- Nicholas Naclerio (person) — Associated with reporting entities
- Illumina Innovation Fund II GP, L.L.C. (company) — Associated with reporting entities
- Illumina Innovation Fund III, L.P. (company) — Mentioned in filing details
FAQ
What specific types of transactions were reported by Illumina Innovation Fund II, L.P. on April 16, 2026?
The filing is a Form 4, indicating a statement of changes in beneficial ownership of securities, but the specific transaction details (e.g., buy, sell, grant) are not provided in this excerpt.
What is the relationship between Nicholas Naclerio and the Illumina Innovation Funds?
Nicholas Naclerio is listed as a reporting person associated with Illumina Innovation Fund II, L.P. and Illumina Innovation Fund II GP, L.L.C.
What is the CIK number for Alamar Biosciences, Inc.?
The CIK number for Alamar Biosciences, Inc. is not explicitly stated in this excerpt, but the CIK numbers for the reporting entities are provided.
What is the business address for Illumina Innovation Fund II, L.P.?
The business address for Illumina Innovation Fund II, L.P. is 500 LINCOLN CENTRE DRIVE, SUITE 110, FOSTER CITY, CA.
What is the significance of a Form 4 filing?
A Form 4 filing with the SEC is required to report any changes in the beneficial ownership of a company's securities by an insider, such as a director, officer, or significant shareholder.
Filing Details
This Statement of Changes in Beneficial Ownership (Form 4) was filed with the SEC on April 21, 2026 by Nicholas Naclerio regarding Alamar Biosciences, Inc. (ALMR). Form 4 filings disclose purchases, sales, or other changes in ownership by company insiders such as officers, directors, and major shareholders.